Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) closed at $37.35 down -1.79% from its previous closing price of $38.03. In other words, the price has decreased by -$1.79 from its previous closing price. On the day, 0.77 million shares were traded. TARS stock price reached its highest trading level at $38.27 during the session, while it also had its lowest trading level at $36.175.
Ratios:
For a deeper understanding of Tarsus Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.85 and its Current Ratio is at 6.93. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 20, 2023, initiated with a Neutral rating and assigned the stock a target price of $19.
On July 18, 2023, William Blair started tracking the stock assigning a Outperform rating and target price of $44.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 18 ’24 when Azamian Bobak R. sold 10,415 shares for $30.60 per share. The transaction valued at 318,699 led to the insider holds 26,456 shares of the business.
Neervannan Seshadri sold 4,879 shares of TARS for $149,297 on Mar 18 ’24. The Chief Operating Officer now owns 64,767 shares after completing the transaction at $30.60 per share. On Mar 18 ’24, another insider, Mottiwala Aziz, who serves as the Chief Commercial Officer of the company, sold 4,766 shares for $30.60 each. As a result, the insider received 145,840 and left with 54,075 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 1410959744 and an Enterprise Value of 1105634176. For the stock, the TTM Price-to-Sale (P/S) ratio is 80.86 while its Price-to-Book (P/B) ratio in mrq is 6.49. Its current Enterprise Value per Revenue stands at 63.371 whereas that against EBITDA is -7.771.
Stock Price History:
The Beta on a monthly basis for TARS is 1.14, which has changed by 1.2772455 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $40.40, while it has fallen to a 52-week low of $12.57. The 50-Day Moving Average of the stock is 8.60%, while the 200-Day Moving Average is calculated to be 61.29%.
Shares Statistics:
For the past three months, TARS has traded an average of 695.11K shares per day and 542500 over the past ten days. A total of 34.21M shares are outstanding, with a floating share count of 30.44M. Insiders hold about 19.42% of the company’s shares, while institutions hold 78.79% stake in the company. Shares short for TARS as of 1713139200 were 7899607 with a Short Ratio of 11.36, compared to 1710460800 on 7195486. Therefore, it implies a Short% of Shares Outstanding of 7899607 and a Short% of Float of 21.68.
Earnings Estimates
Tarsus Pharmaceuticals Inc (TARS) is currently under the scrutiny of 8.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$1.2 for the current quarter, with a high estimate of -$0.89 and a low estimate of -$1.32, while EPS last year was -$0.88. The consensus estimate for the next quarter is -$1.07, with high estimates of -$0.92 and low estimates of -$1.31.
Analysts are recommending an EPS of between -$3.3 and -$4.93 for the fiscal current year, implying an average EPS of -$4.18. EPS for the following year is -$1.88, with 7.0 analysts recommending between -$0.35 and -$3.57.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $17.46M this quarter.It ranges from a high estimate of $20.1M to a low estimate of $14.9M. As of the current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $3.12MFor the next quarter, 8 analysts are estimating revenue of $23.59M. There is a high estimate of $26.27M for the next quarter, whereas the lowest estimate is $18.99M.
A total of 8 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $113.51M, while the lowest revenue estimate was $75M, resulting in an average revenue estimate of $99.74M. In the same quarter a year ago, actual revenue was $17.45MBased on 7 analysts’ estimates, the company’s revenue will be $200.61M in the next fiscal year. The high estimate is $239.87M and the low estimate is $175M.
